Document:

Filed by Bowne Pure Compliance

Exhibit 10.2

CONSULTING AGREEMENT

This Consulting Agreement (the “Agreement”) is effective as of this 1st day of July, 2008 (the
“Effective Date”), by and between Spectrum Pharmaceuticals, Inc. (“Spectrum”) located at 157
Technology Dr., Irvine California 92618, USA, and Luigi Lenaz, M.D. (“Consultant”), residing at
                                                                                .

AGREEMENT

In consideration of the covenants set forth below, the parties agree as follows:

	1.	 	Consulting Services. Consultant will assist Spectrum by providing strategic advice on
clinical development and on drug candidates. From the Effective Date through December 31,
2008, Consultant will provide up to 10 days per month of service; and effective January 1,
2009 through December 31, 2009, up to 5 days per month of service.

	 
	2.	 	Compensation. Spectrum will compensate Consultant as follows:

	 	•	 	Spectrum will pay Consultant $10,000 per month from the Effective date through
December 31, 2008; $5,000 per month through December 31, 2009; and thereafter at a rate
of $400 per hour. Any services provided by Consultant to Spectrum in excess of the
maximum number of days per month for each year described in Section 1 above will be
compensated at a rate of $400 per hour. 50% of Consultant’s travel time during any
travel assignment hereunder, including visits to Spectrum’s office, will be deemed to
be time incurred in the performance of services hereunder.

	 
	 	•	 	Spectrum will also reimburse Consultant for all travel and other out of pocket
expenses reasonably incurred by Consultant in connection with his consultation
services, so long as, in the case of a travel assignment, the assignment is undertaken
at the Spectrum’s request or otherwise preapproved by Spectrum in advance. Appropriate
documentation should be forwarded to Spectrum showing expenses, substantially in
accordance with Spectrum documentation requirements applicable to its employees in the
ordinary course.

	3.	 	Term. The term of this Agreement is through December 31, 2010. Thereafter, the Agreement may
be renewed for additional periods by mutual agreement of the parties. Notwithstanding the
foregoing, either party has the right to terminate the relationship at any time on fifteen
(15) days advance notice specifying the effective date of such termination. In the event of
any such termination, compensation will be paid for the services rendered and expenses
incurred by Consultant for the period up to and including the date of such termination.
During the term of the Agreement, Consultant’s restricted stock grants will continue to vest
in accordance with their original scheduled terms. In addition, if Spectrum terminates this
Agreement prior to December 31, 2010, all of the Consultant’s unvested shares of restricted
stock shall fully vest on the date of termination. Consultant acknowledges that such vesting
with trigger a tax event which will be reported to the IRS on a Form W-2. Any tax
withholding required will be paid to Spectrum.

Spectrum Pharmaceuticals Inc. 157 Technology Drive Irvine, CA 92618

Tel (949) 788-6700 Fax (949) 788-6706

 

 

 

Spectrum Pharmaceuticals, Inc.

Consulting Agreement

	4.	 	Independent Contractor Status and Compliance with Laws. Consultant will be an independent
contractor and will have sole control of the manner and means of performing Consultant
obligations under this Agreement. Consultant will not be considered an agent or legal
representative of Spectrum. Consultant shall have no authority to commit or bind Spectrum in
any way. Consultant will be solely responsible for paying all applicable taxes of any manner,
including social security and other social welfare taxes or contributions that may be due on
amounts received by Consultant hereunder, not including, for the avoidance of doubt, any taxes
or other levies that may be imposed on Spectrum with respect to its payment of such amounts to
consultant.

	 
	5.	 	Immigration Status. As Consultant is an independent contractor, the parties agree that
Spectrum is not responsible for verification of the work authorization of the Consultant
and/or the Consultant’s employees, if any. Consultant represents and warrants that the
Consultant and any employees of the Consultant used by Consultant to perform the services
hereunder, are authorized to work and are not acting and will not act during the terms of the
Agreement in violation of the Immigration Reform and Control Act of 1986 and its amendments
and the regulations there under. Consultant will indemnify and hold Spectrum harmless against
all liabilities, including any fines, penalties, and or attorney’s fees incurred because
Consultant and/or Consultant’s employees are not authorized for employment in the United
States.

	 
	6.	 	Absence of Conflicts. Consultant warrants that Consultant is free to provide consulting
services in accordance with the terms of this Agreement without violation of obligation to any
third party, and by providing consultation services to Spectrum Consultant will have no
conflict of interest with any third party. For the avoidance of doubt, Consultant may, in the
capacity of an independent contractor, provide services to a third party in the oncology or
other medical/pharmaceutical area, which shall not, in and of itself, be deemed a conflict of
interest.

	 
	7.	 	Rights in Work Product. Spectrum will own all right, title and interest in all data,
inventions, discoveries, drug product, formulations, product designs, know-how, formulas,
ideas, studies, reports, documents, publications and the like or other information created, by
Consultant in the course of, or otherwise arising from, his consulting services hereunder. For
the purpose of implementing the foregoing provision, Consultant agrees, as necessary, to
assign and hereby assigns to Spectrum his rights, if any, in all copyrights, patents,
trademarks, or other intellectual property of any kind referred to by such provision. If
applicable, Consultant shall assist Spectrum in applying for, maintaining, or otherwise
securing legal protection for the same, and Consultant agrees to execute any papers, documents
or letters necessary to vest title in the intellectual property in Spectrum.

	 
	8.	 	Non-compete. Consultant represents that it has disclosed, and will disclose, to Spectrum any
agreements that it has, or will have, to work on products that are, or will be, in direct
competition with products being developed or marketed by Spectrum.

	 
	9.	 	Hiring of Spectrum Employees. During the term of this Agreement and for a period of one (1)
year from the termination of this Agreement, Consultant will not, directly or indirectly,
solicit for employment or hire for employment any employee of Company with whom Consultant has
had contact or who becomes known to Consultant, whether before or after the date hereof, in
connection with providing the consulting services set forth herein.

Spectrum Pharmaceuticals Inc. 157 Technology Drive Irvine, CA 92618

Tel (949) 788-6700 Fax (949) 788-6706

 

Page 2

 

Spectrum Pharmaceuticals, Inc.

Consulting Agreement

	10.	 	Severability. Should any part of this Agreement be unenforceable or in conflict with the
applicable laws or regulations of any jurisdiction, the invalid or unenforceable part or
provision will be replaced with a provision that accomplishes, to the extent possible, the
original business purpose of such part or provision in a valid and enforceable manner, and the
remainder of this Agreement will remain binding upon the parties.

	 
	11.	 	Governing Law. This Agreement shall be governed by and construed in accordance with the laws
of the State of California without giving effect to the principles of conflict of laws.

	 
	12.	 	Entire Agreement, Survival of Certain Provisions and Amendments. This Agreement represents
the entire understanding between the parties as of the date of this Agreement with respect to
the subject matter described, other than the confidentiality agreement dated April 28, 2008,
by and between Consultant and Spectrum, and supersedes all prior agreements, negotiations,
understandings, representations, statements, and writings between the parties. Sections 6, 7,
8, 10, 11 and this section 12 will survive any expiration or termination of this Agreement.
No modification, alteration, waiver or change in any of the terms of this Agreement will be
valid or binding upon the parties unless made in writing and specifically referring to this
Agreement and signed by each of the parties listed.

	 
	13.	 	Assignment. Consultant shall not assign, transfer, or subcontract this Agreement or any of
his obligations hereunder without the prior written consent of Spectrum.

	 
	14.	 	Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed
to be an original, but all of which together shall be deemed to be one and the same
instrument. This Agreement may also be executed by exchange of facsimile transmissions
between the parties.

[SIGNATURE PAGE TO FOLLOW]

Spectrum Pharmaceuticals Inc. 157 Technology Drive Irvine, CA 92618

Tel (949) 788-6700 Fax (949) 788-6706

 

Page 3

 

Spectrum Pharmaceuticals, Inc.

Consulting Agreement

Agreed and Accepted as of the date set forth below:

	 	 	 	 	 	 	 
	SPECTRUM PHARMACEUTICALS, INC.	 	LUIGI LENAZ, M.D.
	 
	 	 	 	 	 	 
	By:

	 	/S/ Rajesh C. Shrotriya, M.D.
	 	By:
	 	/S/ Luigi Lenaz, M.D.
	 

	 	 
	 	 	 	 
	 

	 	Rajesh C. Shrotriya, M.D.
	 	 	 	Signature
	 

	 	CEO and President	 	 	 	 
	 
	 	 	 	 	 	 
	Date:

	 	April 28, 2008
	 	Date:
	 	April 28, 2008
	 

	 	 
	 	 	 	 

Spectrum Pharmaceuticals Inc. 157 Technology Drive Irvine, CA 92618

Tel (949) 788-6700 Fax (949) 788-6706

 

Page 4exhibit101.htm

    

      Exhibit
10.1

      

      

                                  
Orion Marine Group, Inc.

                                  Non-employees
Director Compensation

      

      On May
22, 2008, the Orion Marine Group, Inc. (“Company”) Board of Directors adopted
the annual non-employee director compensation program (effective beginning in
and for 2008) summarized below:

      

      
        	
                A.  

              	
                Board of
      Directors

              

      

      

      
        	
                1.  

              	
                Cash
      Compensation

              

      

      
        	
                a.  

              	
                Annual
      Retainer: $35,000 (increase of
$5000).

              

      

      
        	
                b.  

              	
                Additional
      Chairman Retainer:  $25,000 (increase of
    $10,000).

              

      

      
        	
                c.  

              	
                Meeting
      Fee: $1,000 per regular meeting; no separate compensation for special
      meetings (unchanged).

              

      

      
        	
                d.  

              	
                Reimbursement
      of travel and related business expenses
  (unchanged).

              

      

      

      
        	
                2.  

              	
                Equity
      Compensation

              

      

      
        	
                a.  

              	
                At
      the particular director’s option, annual grants to each director of
      Company restricted stock or stock options with an economic value of
      $35,000 at the time of grant to each
director.

              

      

      
        	
                b.  

              	
                Previously,
      there was not a program of periodic equity grants to
      directors.

              

      

      
        	
                c.  

              	
                Grants
      for 2008 will occur in early September
2008.

              

      

      

      
        	
                B.  

              	
                Audit
      Committee

              

      

      

      
        	
                1.  

              	
                Chair
      Annual Retainer: $12,500 (increase of
$2,500).

              

      

      
        	
                2.  

              	
                Member
      Annual Retainer: $ 7,000
(unchanged).

              

      

      
        	
                3.  

              	
                Meeting
      Fee: $1,000 per regular meeting; no separate compensation for special
      meetings (unchanged).

              

      

      

      
        	
                C.  

              	
                Compensation
      Committee

              

      

      

      
        	
                1.  

              	
                Chair
      Annual Retainer: $7,000 (previously, no separate
  retainer).

              

      

      
        	
                2.  

              	
                Member
      Annual Retainer: $5,000
(unchanged).

              

      

      
        	
                3.  

              	
                Meeting
      Fee: $1,000 per regular meeting; no separate compensation for special
      meetings (unchanged).

              

      

      

      
        	
                D.  

              	
                Nominating &
      Governance Committee

              

      

      

      
        	
                1.  

              	
                Chair
      Annual Retainer: $7,000 (previously, no separate
  retainer).

              

      

      
        	
                2.  

              	
                Member
      Annual Retainer: $5,000 (previously, no
  retainer).

              

      

      
        	
                3.  

              	
                Meeting
      Fee: $1,000 per regular meeting; no separate compensation for special
      meetings (previously, no
payment).

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}]]